Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;101(7):e303-5.
doi: 10.3324/haematol.2016.144840. Epub 2016 Apr 21.

Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B

Geffen Kleinstern  1 , Rania Abu Seir  2 , Riki Perlman  3 , Ziad Abdeen  4 , Areej Khatib  5 , Husein Elyan  6 , Eldad J Dann  7 , Meirav Kedmi  8 , Martin Ellis  9 , Arnon Nagler  8 , Gail Amir  10 , Dina Ben Yehuda  3 , Rifaat Safadi  11 , Ora Paltiel  12
Affiliations

Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B

Geffen Kleinstern et al. Haematologica. 2016 Jul.
No abstract available

Keywords: HBV; case-control study; family history; immune response; non Hodgkin lymphoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Forest plots showing the odds ratio (OR) and 95% confidence interval (CI) for combinations of hepatitis B (HBV) biomarkers and their associations with overall B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) for the pooled populations (Israelis and Palestinians). ORs were stratified by population (Israelis, Palestinians), sex and age categories (four-year grouping); adjusted for marital status, education (yrs), family history of hematopoietic malignancies in first-degree relatives. Hepatitis biomarkers: hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc) and hepatitis B surface antibodies (anti-HBs). Bold font indicates P<0.05.
Figure 2.
Figure 2.
Forest plots showing the odds ratio (OR) and 95% confidence interval (CI) for combinations of hepatitis B (HBV) biomarkers and their associations with overall B-cell non- Hodgkin lymphoma (B-NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) for the pooled populations (Israelis and Palestinians). ORs were stratified by population (Israelis, Palestinians), sex and age categories (four-year grouping); adjusted for marital status, education (yrs), family history of hematopoietic malignancies in first-degree relatives. HBV biomarkers: hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc) and hepatitis B surface antibodies (anti-HBs). Combinations: Occult hepatitis B infection (OBI: anti-HBc+, HBsAg−; Naturally immune (anti- HBc+, anti-HBs+); Immune via vaccine (anti-HBc−, anti-HBs+); Lack of immune response (anti-HBc+, anti-HBs−); Bold font indicates P<0.05.
See this image and copyright information in PMC

References

    1. World Health Organization. Hepatitis B. World Health Organization; [cited 2015 Dec 23]. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html
    1. Becker N, Schnitzler P, Boffetta P, et al. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. J Cancer Res Clin Oncol. 2012;138(12):1993–2001. - PMC - PubMed
    1. Okan V, Yilmaz M, Bayram A, et al. Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders. Int J Hematol. 2008;88(4):403–408. - PubMed
    1. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11(9):827–834. - PMC - PubMed
    1. Park SC, Jeong S-H, Kim J, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin’s lymphoma in Korea. J Med Virol. 2008;80(6):960–966. - PubMed

Publication types